| abstract |
The disclosure relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects, using therapeutic antibodies that bind to the human CD 19 antigen and that mediate human ADCC. The present disclosure relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgG1 or IgG3 human isotype. The present disclosure relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present disclosure also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present disclosure relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD 19 antibodies. |